-
Mashup Score: 0
Abstract. Introduction: Diffuse large B cell lymphoma (DLBCL) patients (pts) with relapsed or refractory (r/r) disease after front line chemoimmunotherapy have
Source: ashpublications.orgCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 0
Abstract. Introduction: Diffuse large B cell lymphoma (DLBCL) patients (pts) with relapsed or refractory (r/r) disease after front line chemoimmunotherapy have
Source: ashpublications.orgCategories: Hem/Oncs, Latest HeadlinesTweet-
@AkivaDiamond @AaronGoodman33 I agree that ICE is more like CHOP. But in the phase I of VICER there was a lot of toxicity https://t.co/Rvg3EKjuAn and now that randomized studies show higher mortality, my enthusiasm for non-randomized phase 2s of ven combos is tempered
-
-
Mashup Score: 1
Two papers in this issue document the changing landscape of multiple myeloma in the wake of improved therapies. In the first, investigators from the PETHEMA gro
Source: ashpublications.orgCategories: Hem/Oncs, Latest HeadlinesTweet-
@AaronGoodman33 @BloodJournal Holy moly! Are the French actually doing this? Quads for all and tandems for high risk with VRD maintenance? I look forward to the day when we base treatment on response (MRD) so we can assess who needs such aggressive therapy. response matters more! https://t.co/LG8OpJjbBt
-
-
Mashup Score: 1Venetoclax Plus R-ICE Chemotherapy for Relapsed/Refractory Diffuse Large B-Cell Lymphoma - Full Text View - ClinicalTrials.gov - 3 year(s) ago
Venetoclax Plus R-ICE Chemotherapy for Relapsed/Refractory Diffuse Large B-Cell Lymphoma – Full Text View.
Source: clinicaltrials.govCategories: Hem/Oncs, Latest HeadlinesTweet-
@AaronGoodman33 I just told a patient last week he might have made a good choice by not enrolling on a trial of VR-ICE for relapsed lymphoma. I was hoping their might be another update at ASH, but no luck https://t.co/BmLBWS8poC
-
-
Mashup Score: 1Reporting of Postprotocol Therapies and Attrition in Multiple Myeloma Randomized Clinical Trials - 3 year(s) ago
This systematic review examines the reporting of postprotocol treatment received by patients enrolled in randomized clinical trials for new-onset or relapsed/refractory multiple myeloma.
Source: jamanetwork.comCategories: Hem/Oncs, Latest HeadlinesTweet-
@ManniMD1 Also completely agree with allowing crossover to actual regimens used in practice and reporting of postprotocol therapies and attrition! https://t.co/A4tEDMJB9S glad someone has been working on this!
-
-
Mashup Score: 2HemOnc.org - A Hematology Oncology Wiki - 3 year(s) ago
Regimens: 3,743 Regimen variants: 5,539 Studies: 6,009 References: 6,578 Solid Tumors Malignant Hematology Pediatrics Transplant Classical Hematology Links to all main disease pages Solid Tumors Breast Oncology Breast cancer Breast cancer, ER-positive Breast cancer, HER2-positive Breast cancer, ER and HER2 co-expressing Breast cancer, triple negative (TNBC) Breast…
Source: hemonc.orgCategories: Hem/Oncs, Latest HeadlinesTweet-
Fantastic!!! I look forward to working with you to improve care for AML with https://t.co/RWuBOlfVh5! https://t.co/u0FZdMxN8N
-
-
Mashup Score: 1
Blockade of programmed death 1 (PD-1) is now established as a standard treatment for relapsed Hodgkin lymphoma, and how this approach can be incorporated into f
Source: ashpublications.orgCategories: Hem/Oncs, Latest HeadlinesTweet-
@AaronGoodman33 https://t.co/4HUMazuUYX
-
@AkivaDiamond @AaronGoodman33 I agree that ICE is more like CHOP. But in the phase I of VICER there was a lot of toxicity https://t.co/Rvg3EKjuAn and now that randomized studies show higher mortality, my enthusiasm for non-randomized phase 2s of ven combos is tempered https://t.co/xQsc4x24DY